Cidara Therapeutics
$221.38
57
+$0.06+0.03% Tuesday 21:00
Statistics
Day High
221.41
Day Low
221.28
52W High
221.42
52W Low
15.22
Volume
2,690,958
Avg. Volume
1,427,880
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Earnings
11MarExpected
Expected EPS
-1.640445
Actual EPS
N/A
Financials
-556.12%Profit Margin
Unprofitable61.08MRevenue
-339.65MNet Income
Analyst Ratings
$176.80Average Price Target
The highest estimate is 200.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy 71%
Hold 29%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CDTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Scynexis
SCYX
Mkt Cap27.67M
AnaptysBio
ANAB
Mkt Cap1.02B
Amphastar Pharmaceuticals
AMPH
Mkt Cap1.19B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Gilead Sciences
GILD
Mkt Cap148.78B
Astrazeneca
AZN
Mkt Cap256.58B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Novartis
NVS
Mkt Cap237.61B
About
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Show more...
CEO
Dr. Jeffrey L. Stein Ph.D.
Employees
38
Country
US
ISIN
US1717572069
Listings
0 Comments
Share your thoughts
FAQ
What is Cidara Therapeutics stock price today?▼
The current price of CDTX is $221.38 USD — it has increased by +0.03% in the past 24 hours. Watch Cidara Therapeutics stock price performance more closely on the chart.
What is Cidara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cidara Therapeutics stocks are traded under the ticker CDTX.
Is Cidara Therapeutics stock price growing?▼
CDTX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Cidara Therapeutics has showed a +1,070.08% increase.
What is Cidara Therapeutics revenue for the last year?▼
Cidara Therapeutics revenue for the last year amounts to 61.08M USD.
What is Cidara Therapeutics net income for the last year?▼
CDTX net income for the last year is -339.65M USD.
How many employees does Cidara Therapeutics have?▼
As of April 01, 2026, the company has 38 employees.
In which sector is Cidara Therapeutics located?▼
Cidara Therapeutics operates in the Health Care sector.
When did Cidara Therapeutics complete a stock split?▼
The last stock split for Cidara Therapeutics was on April 24, 2024 with a ratio of 1:20.
Where is Cidara Therapeutics headquartered?▼
Cidara Therapeutics is headquartered in San Diego, US.